Veracyte announced eight studies tied to ASTRO 2026 in Boston from September 26–30, 2026.

The company’s Decipher Prostate Genomic Classifier test is used to identify patients' risk of progression and likelihood of benefiting from treatment intensification.

Elai Davicioni, Ph.D., said the breadth of research being presented at ASTRO underscores the growing role of genomic information in helping clinicians navigate complex prostate cancer treatment decisions.

Highlights

  • Veracyte announced eight studies for ASTRO 2026.
  • ASTRO 2026 is scheduled for Boston from September 26–30, 2026.
  • One Veracyte statement says genomic information can help clinicians navigate complex prostate cancer treatment decisions.